HC Wainwright upgraded shares of Solaris Resources (CVE:SLS – Free Report) to a strong-buy rating in a research report sent to investors on Monday morning, Zacks.com reports. HC Wainwright also issued estimates for Solaris Resources’ FY2024 earnings at ($0.45) EPS and FY2025 earnings at ($0.47) EPS.
A number of other equities research analysts have also recently issued reports on the company. National Bank Financial upgraded Solaris Resources to a strong-buy rating in a research note on Monday, June 10th. Maxim Group upgraded shares of Solaris Resources to a strong-buy rating in a research report on Wednesday, July 3rd.
Check Out Our Latest Report on Solaris Resources
Solaris Resources Stock Performance
Solaris Resources Company Profile
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
- Five stocks we like better than Solaris Resources
- 5 Top Rated Dividend Stocks to Consider
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- How to Buy Cheap Stocks Step by Step
- Jeff Brown’s Exegesis AI Stock Picks
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.